Dendreon (DNDN) - FREE Research Report Rocco Lindsay who is EVP, Corporate Communications at Dendreon sold 8,207 shares at $2.94 on Jan. 10, 2014. Following this transaction, the EVP, Corporate Communications owned 112,500 shares meaning that the stake was reduced by 6.8% with the 8,207-share transaction. The shares most recently traded at $3.24, up $0.30, or 9.2% since the insider transaction. The average volume for Dendreon has been 4.4 million shares per day over the past 30 days. Dendreon has a market cap of $458.3 million and is part of the health care sector and drugs industry. Shares are unchanged year-to-date as of the close of trading on Friday. Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients. Currently there is 1 analyst that rates Dendreon a buy, 8 analysts rate it a sell, and 8 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on DNDN - FREE TheStreet Quant Ratings rates Dendreon as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full Dendreon Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts